Maravai LifeSciences Holdings Inc

MRVI

2.870USD

-0.220-7.12%

Close 03/30, 16:00（ET）Quotes delayed by 15 min

Maravai LifeSciences Holdings Inc's Score

Industry at a Glance

Industry Ranking

61 / 391

Overall Ranking

170 / 4542

Industry

Biotechnology & Medical Research

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Maravai LifeSciences Holdings Inc Highlights

StrengthsRisks

Maravai LifeSciences Holdings, Inc. is a life sciences company providing critical products to enable the development of drug therapies, diagnostics and novel vaccines and to support research on human diseases. Its segments include Nucleic Acid Production Segment and Biologics Safety Testing Segment. The Nucleic Acid Production segment is focused on the manufacturing and sale of highly modified nucleic acids products to support the needs of customers’ research, therapeutic and vaccine programs. This segment’s business units include TriLink Discovery, TriLink GMP, Glen Research and Alphazyme. The Biologics Safety Testing segment is focused on manufacturing and selling biologics safety and impurity tests and assay development services that are utilized by its customers in their biologic drug manufacturing activities. This segment’s business is comprised of Cygnus Technologies. It serves various companies, including biopharmaceutical, vaccine, diagnostics and cell and gene therapy.

Fairly Valued

The company’s latest PE is -3.16, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 130.99M shares, decreasing 22.71% quarter-over-quarter.

Held by CI Select Canadian Equity Fund

Star Investor CI Select Canadian Equity Fund holds 14.30K shares of this stock.

Analyst Rating

Based on 11 analysts

Buy

Current Rating

4.333

Target Price

+40.24%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current financial score of Maravai LifeSciences Holdings Inc is 7.00, ranking 147 out of 391 in the Biotechnology & Medical Research industry. Its financial status is stable, and its operating efficiency is average. Its latest quarterly revenue reached 49.87M, representing a year-over-year decrease of 11.59%, while its net profit experienced a year-over-year decrease of 36.47%.

Score

Industry at a Glance

Previous score

7.00

Change

0



Financials

6.70

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.98

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

7.64

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

6.53

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.15

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

The current valuation score of Maravai LifeSciences Holdings Inc is 7.48, ranking 113 out of 391 in the Biotechnology & Medical Research industry. Its current P/E ratio is -3.16, which is -1774.62% below the recent high of 52.87 and -261.69% above the recent low of -11.42.

Score

Industry at a Glance

Previous score

7.48

Change

0

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 61/391

Relevant data have not been disclosed by the company yet.

The current earnings forecast score of Maravai LifeSciences Holdings Inc is 7.27, ranking 306 out of 391 in the Biotechnology & Medical Research industry. The average price target is 4.00, with a high of 5.00 and a low of 2.00.

Score

Industry at a Glance

Previous score

7.27

Change

0

Support & Resistance

Relevant data have not been disclosed by the company yet.

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

The current price momentum score of Maravai LifeSciences Holdings Inc is 6.03, ranking 282 out of 391 in the Biotechnology & Medical Research industry. Currently, the stock price is trading between the resistance level at 3.56 and the support level at 2.50, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.20

Change

-0.17

Support & Resistance

Relevant data have not been disclosed by the company yet.

Institutional Confidence

Currency: USD Updated: 2026-03-27

The current institutional shareholding score of Maravai LifeSciences Holdings Inc is 10.00, ranking 1 out of 391 in the Biotechnology & Medical Research industry. The latest institutional shareholding proportion is 90.33%, representing a quarter-over-quarter increase of 1.58%. The largest institutional shareholder is The Vanguard, holding a total of 7.17M shares, representing 4.90% of shares outstanding, with 39.42% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

0

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

GTCR Golder Rauner, LLC

20.15M

--

12 West Capital Management, L.P.

12.52M

--

Braidwell LP

8.35M

--

Hudson View Capital LLC

8.94M

+30.22%

BlackRock Institutional Trust Company, N.A.

7.69M

-8.54%

The Vanguard Group, Inc.

Star Investors

7.13M

-24.04%

T. Rowe Price Investment Management, Inc.

6.16M

+132.94%

Mackenzie Financial Corporation

6.07M

--

Renaissance Technologies LLC

Star Investors

4.32M

+3.15%

Monaco asset management S.A.M.

3.66M

+315.04%



1

2



The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Biotechnology & Medical Research domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Maravai LifeSciences Holdings Inc is 4.60, ranking 77 out of 391 in the Biotechnology & Medical Research industry. The company's beta value is 0.39. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.

Maravai LifeSciences Holdings Inc

MRVI

6.99 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Alkermes Plc

ALKS

8.42 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Madrigal Pharmaceuticals Inc

MDGL

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

BioCryst Pharmaceuticals Inc

BCRX

8.27 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Day One Biopharmaceuticals Inc

DAWN

8.26 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

IQVIA Holdings Inc

IQV

8.21 /10

Score

Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment